Medicare Part D plans cover popular obesity drugs if they are used for an additional medically accepted purpose as approved ...

Biopharma executives shared their thoughts on the potential impacts of the new administration; Annalee Armstrong recaps JPM ...

T he newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ...

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat ...

About 140,400 obese patients in Massachusetts were prescribed medications like Wegovy and Zepbound in 2024, a 255 percent ...

As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has ...

Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...

The stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY ...

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less ...

Novo Nordisk said on Friday a late-stage trial with a high-dose version of its weight loss drug semaglutide helped overweight ...

Miracle drug innovations — such as those that sparked the meteoric rise of Wegovy and Zepbound — could come every couple of ...